Clinical activity of tipifarnib in hematologic malignancies

Elias Jabbour, Hagop Kantarjian, Jorges Cortes

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Farnesyltransferase inhibitors are a novel class of anticancer agents that competitively inhibit farnesyltransferase. Initially developed to inhibit the farnesylation that is necessary for Ras activation, their mechanism of action seems to be more complex, involving other proteins unrelated to Ras. Of the four classes of farnesyltransferase inhibitors, at least three agents have been investigated in hematologic malignancies. Tipifarnib (R-115777), an orally administered non-peptidomimetic farnesyltransferase inhibitor, has shown promising clinical activity. Preliminary results from clinical trials demonstrate enzyme target inhibition, an acceptable toxicity profile and promising evidence of clinical activity. Ongoing studies will better determine the mechanism of action of tipifarnib and the role of combination with other agents, defining its place in the therapeutic arsenal of hematologic disorders.

Original languageEnglish (US)
Pages (from-to)381-392
Number of pages12
JournalExpert Opinion on Investigational Drugs
Issue number3
StatePublished - Mar 1 2007
Externally publishedYes


  • Farnesyltransferase inhibitors
  • Leukemia
  • Ras pathway
  • Signal transduction
  • Tipifarnib

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Clinical activity of tipifarnib in hematologic malignancies'. Together they form a unique fingerprint.

Cite this